Enliven Therapeutics
IPOSmall Molecule Kinase Inhibitors
Public · United States · $305.0M raised
- Business Model
- B2B
- Website
- enliventherapeutics.com
- Total Funding
- $305.0M
- Last Round
- $165.0M Corporate RoundFeb 2023
- Rounds
- 3
- Type
- Public
About
Clinical-stage biotech developing small molecule kinase inhibitors targeting BCR-ABL and HER2 for cancer treatment.
Summary
Enliven Therapeutics is a Biotech company based in United States. It has raised $305.0M in total across 3 rounds, most recently a $165.0M Corporate Round round in Feb 2023. Investors include OrbiMed and Fairmount.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jan 2024
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...